4 completed, 1 active not recruiting, 1 terminated, 1 unknown. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 4, Active not recruiting 1, Terminated 1, Unknown 1 |
Follow Prothya Biosolutions: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema Dupilumab - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 4 | Active not recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 216 | 2023-08-14 | 2026-10-29 |
| Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS Wide Excision, Adalimumab Injection - Hidradenitis Suppurativa | Phase 4 | Unknown | Erasmus Medical Center | 128 | 2018-07-31 | 2019-02-08 |
| C1-inhibitor in Allergic ASThma Patients C1-inhibitor, Saline, Antibiotics - Asthma | Phase 4 | Terminated | T. van der Poll | 37 | 2016-11-16 | 2020-06-24 |
| Towards Personalized Dosing of Natalizumab in Multiple Sclerosis Natalizumab - Multiple Sclerosis | Phase 4 | Completed | Amsterdam UMC, location VUmc | 61 | 2016-11-03 | 2019-07-12 |
| Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response intravenous immunoglobulins, antibiotics - IgG Deficiency, Infections | Phase 4 | Completed | Prothya Biosolutions | 55 | 2007-11-01 | 2015-04-06 |
| Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX) human coagulation Factor IX - Hemophilia B | Phase 4 | Completed | Prothya Biosolutions | 12 | 2003-05-01 | 2007-08-30 |
| Study Use of PPSB-SD and VP-VI in Patients With Anticoagulant Therapy and Undergoing Acute CPB Surgery PPSB-SD - CPB, Oral Anticoagulant Therapy | Phase 4 | Completed | Prothya Biosolutions | 40 | 2002-03-01 | 2023-12-07 |
Angioedemas, Hereditary (1) · Asthma (1) · Dermatitis, Atopic (1) · Hemophilia B (1) · Hidradenitis Suppurativa (1) · IgG Deficiency (1) · Infections (1) · Multiple Sclerosis (1)
Anti-Bacterial Agents (2) · Adalimumab (1) · Ciprofloxacin (1) · Complement C1 Inhibitor Protein (1) · Factor IX (1) · Immunoglobulins, Intravenous (1) · Metronidazole (1) · Natalizumab (1) · SERPING1 protein, human (1) · Sodium Chloride (1) · Vancomycin (1) · dupilumab (1)
Netherlands (6) · Belgium (1)
DirkJan Hijnen, MD PhD (1) · E AM Sanders, PhD, MD (1) · E P Mauser-Bunschoten, MD, PdD (1) · J T van Dissel, PhD, MD (1) · Joep Killestein, Dr. (1) · Louise AA Gerbens, MD PhD (1) · Martijn van Doorn, MD, PhD (1) · P FW Strengers, MD (1) · Phyllis I Spuls, MD PhD (1) · T W Kuijpers, PhD, MD (1)
2023 (1)